Carolyn Owen, MD

Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.

Carolyn Owen, MD, discusses minimal residual disease as an area of research in the chronic lymphocytic leukemia space.

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia. .

Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.